I didn’t think it was flash TBH. Here is why:
despite the KP and CMS the inclusion we managed to do less TLT than previous year. Cure covid knocked out 2 months - but there was nothing to show me that KP deal provided any significant volume. Maybe the inclusion and testing of systems took longer than anticipated. This deal was touted as a company maker - I’m not seeing it.
No mention of the 20m of invoiced tests.
opex costs are running at 24m. Unless there is a serious cash injection we will be looking at a capital raise in the next few months. Based on that rate we have expended $4m already this FY.
We were told that March was a stellar month - 69% greater than average FY21. Crude numbers put this at 1500 tests in March. This drops to 1200 tests when you remove non commercial ratio.
If we assume 10% growth per month this is ~19000 tests per year. Which is $15M. Not huge uptake if you ask me.
management need to release quarterly TLT throughput figures. Releasing once a year is rubbish.
Summary for me was the Result showed treading water with no impact from large volume healthcare organisations.
- Forums
- NZX - By Stock
- PEB
- Ann: FLLYR: PEB: PEB Financial Results for the 12 months to 31 March 2021
Ann: FLLYR: PEB: PEB Financial Results for the 12 months to 31 March 2021, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PEB (NZSX) to my watchlist
|
|||||
Last
8.5¢ |
Change
0.002(2.41%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
8.4¢ | 8.7¢ | 8.4¢ | $78.45K | 926.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
0 | 374 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.2¢ | 80012 | 0 |
Last trade - 12.43pm 12/07/2024 (20 minute delay) ? |
Featured News
PEB (NZSX) Chart |